Evidence map›Paper›PMID 34234609›Full record

ReviewJournal of blood medicine2021

Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma.

Karun Neupane, Ahsan Wahab, Adeel Masood, Tehniat Faraz, Saman Bahram, Hamid Ehsan, Abdul Hannan, Faiz Anwer

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of blood medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07002099 (Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma), which is not on this map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07002099 phase2recruitingnot on this mapstarted 2025, after this paper: background citation

Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study

TypeinterventionalSponsorSecond Affiliated Hospital of Soochow UniversityRan2025 to 2028Enrolled26ConditionsLymphomasArmsSelinexor + High-dose Methotrexate + Rituximab + WBRT
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. HibeRNAtion: HIV-1 RNA Metabolism and Viral Latency.Frontiers in cellular and infection microbiology · 2022
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 3 countries.

Karun NeupaneDepartment of Internal Medicine, Manipal College of Medical Sciences, Pokhara, Gandaki, Nepal.ORCID 0000-0001-7950-5287
Ahsan WahabDepartment of Internal Medicine, Baptist Medical Center South/University of Alabama at Birmingham, Montgomery, AL, USA.
Adeel MasoodDepartment of Internal Medicine, Tidal Health Peninsula Regional, Salisbury, MD, USA.ORCID 0000-0001-7085-777X
Tehniat FarazDepartment of Biochemistry, Dow University of Health Sciences, Karachi, Sindh, Pakistan.ORCID 0000-0002-8240-6973
Saman BahramDepartment of Internal Medicine, Dow University of Health Sciences, Karachi, Sindh, Pakistan.
Hamid EhsanDepartment of Biomedic Sciences/Biohazardous Threat Agents & Emerging Infectious Diseases, Georgetown University, Washington, DC, USA.ORCID 0000-0002-4607-3171
Abdul HannanDepartment of Hematology/Oncology, Simmons Cancer Institute at Southern Illinois University School of Medicine, Springfield, IL, USA.
Faiz AnwerDepartment of Hematology/Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
Dow University of Health Sciences · PKCleveland Clinic · USGeorgetown University · USManipal College of Medical Sciences · NPPeninsula Regional Medical Center · USSouthern Illinois University School of Medicine · USUniversity of Alabama at Birmingham · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment options are limited for multiple myeloma patients who have developed four/five drug-refractory disease. Selinexor (Sel) and belantamab mafodotin (belamaf) were recently approved by the US FDA for treatment of RRMM. The toxicity profile of these drugs is a concern since these agents are used in patients who have already undergone multiple lines of treatment. In this review, we discuss the toxicity profile and strategies for the management of toxicities of Sel and belamaf for the treatment of RRMM. We conducted a comprehensive literature search on PubMed, Embase, Cochrane, and Clinicaltrials.gov using the terms "selinexor", "belantamab", "belamaf", and "multiple myeloma" without applying any limitations based on the date of the study, language, or country of origin. The most common hematological toxicity associated with these two drugs is thrombocytopenia. Cytopenias, constitutional symptoms, gastrointestinal effects, and hyponatremia are the major toxicities of Sel. Keratopathy and anemia are the major toxicities of belamaf. Treatment modifications and dose interruption are usually needed when side effects are more than grade II. As these are newer drugs with limited data, continuous surveillance and monitoring are warranted during the treatment course with early mitigation strategies.

Indexed as

hematological malignancyocular toxicityrelapsed and refractory multiple myelomasafetytreatment

Identifiers

PMID34234609
PMCPMC8257048
OpenAlexW3176479708

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.